LCP1 and metabolic dysfunction-associated steatotic liver disease: LCP-1 has never been investigated in interstitial diseases, but it is up-regulated in the serum of patients with Nonalcoholic fatty liver disease (NAFLD) that may lead to the development of liver cirrhosis and fibrosis.